Except for CRC patients with defective mismatch repair/microsatellite instability-high (dMMR/MSI-H) and POLD1/POLE mutations, there are still patients who are expected to benefit from ICIs treatment. This evidence concerns the gene POLD1 and colorectal carcinoma.